Paper Review Records
All Paper Review Records
5 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
222
days
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
AuthorsNele Goeyvaerts; Per Olsson Gisleskog; Martine Neyens; Juan José Perez Ruixo; Saberi Rana Ali; Iolanda Cirillo; Oliver Ackaert
Affiliations1. Johnson & Johnson Beerse Belgium; 2. POG Pharmacometrics London UK; 3. Johnson & Johnson Madrid Spain; 4. Johnson & Johnson Titusville New Jersey USA; 5. Johnson & Johnson Raritan New Jersey USA
81
days
Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study
AuthorsKouki Tomari; Ruud H. J. Verstegen; Cintia Cruz; Erin Chung; Aleena Azim; Shinya Ito; Tamorah R. Lewis
Affiliations1. Division of Clinical Pharmacology & Toxicology The Hospital for Sick Children Toronto Ontario Canada; 2. Department of Paediatrics University of Toronto Toronto Ontario Canada; 3. Division of Rheumatology The Hospital for Sick Children Toronto Ontario Canada; 4. Department of Pharmacy The Hospital for Sick Children Toronto Ontario Canada; 5. Graduate Department of Pharmaceutical Sciences University of Toronto Toronto Ontario Canada; 6. Child Health Evaluative Services The SickKids Research Institute Toronto Ontario Canada; 7. Faculty of Arts & Science University of Toronto Toronto Ontario Canada; 8. Translational Medicine, Research Institute Hospital for Sick Children Toronto Ontario Canada
80
days
A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients
AuthorsClara Laffitte Redondo; Venceslas Bourdin; Abd El Kader Ait Tayeb; Sihem Benaboud; Inès Martins; Caroline Joyau; Myriam Benhamida; Isabelle Sermet‐Gaudelus; Clémence Martin; Pierre Régis Burgel; Céline Verstuyft; Laurent Chouchana; Estelle Ayme‐Dietrich
Affiliations1. Service de Médecine Génomique et Pharmacogénomique CHU Kremlin Bicêtre, APHP Paris France; 2. Centre Régional de Pharmacovigilance, Service de Pharmacologie, Hôpital Cochin, AP‐HP, Université de Paris; Réseau Français de Pharmacovigilance Paris France; 3. Service de Pharmacologie Clinique Hôpital Cochin, AP‐HP, Université de Paris‐Cité Paris France; 4. Centre Régional de Pharmacovigilance, Service de Pharmacologie Clinique, Institut de Biologie CHU Hôtel Dieu Nantes France; 5. Centre de Ressources et de Compétence pour la Mucoviscidose Hôpital Mère‐Enfant Nantes France; 6. INSERM U1151, Université Paris Cité, Hôpital Necker Enfants Malades, APHP Paris France; 7. Institut Cochin, Université Paris Cité, Inserm U1016 Paris France; 8. Université Paris Cité Inserm UMR‐S 1343, Pharmacologie et évaluations des thérapeutiques chez l'enfant et la femme enceinte Paris France; 9. Laboratoire de Pharmacologie et Toxicologie NeuroCardiovasculaire, UR7296, Hôpitaux Universitaires de Strasbourg Université de Strasbourg Strasbourg France
62
days
Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children
AuthorsMichael Rieder
Affiliations1. Departments of Paediatrics, Physiology & Pharmacology and Medicine University of Western Ontario London Ontario Canada; 2. Division of Paediatric Clinical Pharmacology, Department of Paediatrics Children's Hospital of Western Ontario London Ontario Canada
150
days
Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants
AuthorsLana Tran; Naihan Chen; Jennifer A. Winton; Kyle T. Matschke; Smita P. Goodman; Kimberly C. Lee; Yuanyuan Zhang; Weiwei Tan
Affiliations1. Pfizer, Inc San Diego California USA; 2. Pfizer (China) R&D Co, Ltd Shanghai China; 3. Pfizer, Inc. Groton Connecticut USA; 4. Pfizer, Inc. Collegeville Pennsylvania USA; 5. Pfizer, Inc. New York New York USA; 6. Arvinas Operations, Inc. New Haven Connecticut USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days